Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H25NO3 |
Molecular Weight | 279.3746 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1
InChI
InChIKey=VRYMTAVOXVTQEF-UHFFFAOYSA-N
InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3
Molecular Formula | C16H25NO3 |
Molecular Weight | 279.3746 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/9711459Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false
http://www.ncbi.nlm.nih.gov/pubmed/1475074
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false
http://www.ncbi.nlm.nih.gov/pubmed/1475074
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction, also was studied, that this drug may be useful to treat ocular disorders such as diabetic retinopathy. It is an alpha1-adrenergic antagonist. Was developed for self-injection therapy in France and marketed in several European countries as Icavex. In the spring 2005 the manufacturer of Icavex decided to withdraw this drug from Europe market, presumable due to its low market shares.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10699651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. | 2000 Mar 15 |
|
[Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients]. | 2001 Feb |
|
Electroacupuncture-induced pressor and chronotropic effects in anesthetized rats. | 2006 Jan 30 |
|
Noradrenergic control of arginine vasopressin release from the ewe hypothalamus in vitro: sensitivity to oestradiol. | 2008 Apr |
|
Oral vasodilators for primary Raynaud's phenomenon. | 2008 Apr 16 |
|
Noradrenergic control of GnRH release from the ewe hypothalamus in vitro: sensitivity to oestradiol. | 2008 Dec |
|
Effects of adrenergic agents on the expression of zebrafish (Danio rerio) vitellogenin Ao1. | 2009 Jul 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Intracavernous injection of moxisylyte at 10, 20 or 30 mg can induce an erection adequate for intercourse in most of the patients
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2522580
Moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue was investigated and compared with other alpha-adrenergic antagonists. Moxisylyte produced a concentration-dependent relaxation of a norepinephrine-induced (1 x 10(-5) M) contraction of the corpus cavernosum tissue. Pretreatment with 1 x 10(-6) M doses of moxisylyte reduced competitively the norepinephrine-induced contraction
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:47:40 GMT 2025
by
admin
on
Mon Mar 31 17:47:40 GMT 2025
|
Record UNII |
PW8QYA7KI0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G04BE06
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
||
|
WHO-VATC |
QC04AX10
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
||
|
WHO-VATC |
QG04BE06
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
||
|
WHO-ATC |
C04AX10
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09090MIG
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
4260
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
10561
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | RxNorm | ||
|
PW8QYA7KI0
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
1538
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
100000080620
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
C87584
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
D013948
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
m7648
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
200-204-1
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL159226
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
DTXSID4023339
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
DB09205
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
1855
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
54-32-0
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY | |||
|
Moxisylyte
Created by
admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |